

AMENDMENTS TO THE CLAIMS:

1. – 39. (Canceled)

40. (Currently Amended) A method of treating cystic fibrosis, comprising:
administering to a patient a formulation comprising an antidepressant selected from the group consisting of a tricyclic antidepressant, and a tetracyclic [[antidepressant-wherein]] antidepressant, wherein the formulation is administered by inhalation.

41. (Canceled)

42. (Previously Presented) The method of claim 40, wherein the antidepressant is a tricyclic antidepressant.

43. (Previously Presented) The method of claim 40, wherein the antidepressant is a tetracyclic antidepressant.

44. (Previously Presented) The method of claim 40, wherein the antidepressant is selected from the group consisting of amitriptyline and imipramine.

45. (Previously Presented) The method of claim 40, wherein the formulation comprises amitriptyline.

46. (Previously Presented) The method of claim 40, wherein the formulation comprises imipramine.

47. (New) A method of treating cystic fibrosis, comprising:
administering to a patient by inhalation, a formulation comprising a carrier and a pharmaceutically active component consisting essentially of an antidepressant selected from the group consisting of a tricyclic antidepressant, and a tetracyclic antidepressant.

48. (New) The method of claim 47, wherein the antidepressant is a tricyclic antidepressant.

49. (New) The method of claim 47, wherein the antidepressant is a tetracyclic antidepressant.

50. (New) The method of claim 47, wherein the antidepressant is selected from the group consisting of amitryptiline and imipramine.

51. (New) The method of claim 47, wherein the formulation comprises amitryptiline.

52. (New) The method of claim 47, wherein the formulation comprises imipramine.